Atrial septal defect (ASD) closure device
Updates to Case Attributes
Atrial septal defects (ASDs) are among the most common congenital heart defects. Left-to-right shunting can lead to right heart enlargement and dysfunction, with some patients developing pulmonary hypertension.
Closure of an atrial septal defect (ASD) is done surgically or, in select patients with a secundum ASD, via a percutaneous device. Contemporary ASD closure devices include the Amplatzer Septal Occluder, Gore CARDIOFORM Septal Occluder, Occlutech ASD Occluder, the Ceraflex ASD Occluder, and the Nit-Occlud ASD-R. Devices previously in use include the CardioSEAL Septal Occlusion System, the STARFlex device, and the Gore HELEX.
Many of these devices use a nickel-titanium alloy called Nitinolnitinol, which is mildly radio-opaqueradiopaque as seen in our patient. This device can be difficult to appreciate in the frontal view, as it overlays the spinal column. It is more easily viewed in the lateral film.
Disclosure: I, Hilary Bowman, have no actual or potential ethical or financial conflict of interest in relation to this device. This case is not intended to be a personal endorsement or recommendation of this product.
This case was submitted with supervision and input from:
Soni C. Chawla, M.D.Associate ProfessorDepartment of Radiological SciencesDavid Geffen School of Medicine at UCLAOlive View - UCLA Medical CenterSylmar, California, United States
-<p>Atrial septal defects (ASDs) are among the most common congenital heart defects. Left-to-right shunting can lead to right heart enlargement and dysfunction, with some patients developing pulmonary hypertension. </p><p>Closure of an atrial septal defect (ASD) is done surgically or, in select patients with a secundum ASD, via a percutaneous device. Contemporary ASD closure devices include the Amplatzer Septal Occluder, Gore CARDIOFORM Septal Occluder, Occlutech ASD Occluder, the Ceraflex ASD Occluder, and the Nit-Occlud ASD-R. Devices previously in use include the CardioSEAL Septal Occlusion System, the STARFlex device, and the Gore HELEX.</p><p>Many of these devices use a nickel-titanium alloy called Nitinol, which is mildly radio-opaque as seen in our patient. This device can be difficult to appreciate in the frontal view, as it overlays the spinal column. It is more easily viewed in the lateral film.</p><p><strong>Disclosure: </strong><em> I, Hilary Bowman, have no actual or potential ethical or financial conflict of interest in relation to this device. This case is not intended to be a personal endorsement or recommendation of this product.</em></p><p>This case was submitted with supervision and input from:</p><p>Soni C. Chawla, M.D.<br>Associate Professor<br>Department of Radiological Sciences<br>David Geffen School of Medicine at UCLA<br>Olive View - UCLA Medical Center</p>- +<p><a title="Atrial septal defects" href="/articles/atrial-septal-defect-2">Atrial septal defects (ASDs)</a> are among the most common <a title="Congenital heart disease" href="/articles/congenital-cardiovascular-anomalies">congenital heart defects</a>. Left-to-right shunting can lead to right heart enlargement and dysfunction, with some patients developing <a title="Pulmonary hypertension" href="/articles/pulmonary-hypertension-1">pulmonary hypertension</a>. </p><p>Closure of an atrial septal defect (ASD) is done surgically or, in select patients with a secundum ASD, via a percutaneous device. Contemporary ASD closure devices include the Amplatzer Septal Occluder, Gore CARDIOFORM Septal Occluder, Occlutech ASD Occluder, the Ceraflex ASD Occluder, and the Nit-Occlud ASD-R. Devices previously in use include the CardioSEAL Septal Occlusion System, the STARFlex device, and the Gore HELEX.</p><p>Many of these devices use a nickel-titanium alloy called nitinol, which is mildly radiopaque as seen in our patient. This device can be difficult to appreciate in the frontal view, as it overlays the spinal column. It is more easily viewed in the lateral film.</p><p><strong>Disclosure: </strong><em> I, Hilary Bowman, have no actual or potential ethical or financial conflict of interest in relation to this device. This case is not intended to be a personal endorsement or recommendation of this product.</em></p><p>This case was submitted with supervision and input from:</p><p>Soni C Chawla, M.D.<br>Associate Professor<br>Department of Radiological Sciences<br>David Geffen School of Medicine at UCLA<br>Olive View - UCLA Medical Center<br>Sylmar, California, United States</p>
References changed:
- 1. Stout KK, Daniels CJ, Aboulhosn JA, Bozkurt B, Broberg CS, Colman JM, Crumb SR, Dearani JA, Fuller S, Gurvitz M, Khairy P. 2018 AHA/ACC guideline for the management of adults with congenital heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Journal of the American College of Cardiology. 2019 Apr 2;73(12):e81-192.
- 1. Stout KK, Daniels CJ, Aboulhosn JA, Bozkurt B, Broberg CS, Colman JM, Crumb SR, Dearani JA, Fuller S, Gurvitz M, Khairy P. 2018 AHA/ACC guideline for the management of adults with congenital heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Journal of the American College of Cardiology. 2019 Apr 2;73(12):e81-192.
- 2. Tobis J, Shenoda M. Percutaneous treatment of patent foramen ovale and atrial septal defects. Journal of the American College of Cardiology. 2012 Oct 30;60(18):1722-32.
- Stout KK, Daniels CJ, Aboulhosn JA, Bozkurt B, Broberg CS, Colman JM, Crumb SR, Dearani JA, Fuller S, Gurvitz M, Khairy P. 2018 AHA/ACC guideline for the management of adults with congenital heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Journal of the American College of Cardiology. 2019 Mar 25;73(12):e81-192.
- 1. Stout KK, Daniels CJ, Aboulhosn JA, Bozkurt B, Broberg CS, Colman JM, Crumb SR, Dearani JA, Fuller S, Gurvitz M, Khairy P. 2018 AHA/ACC guideline for the management of adults with congenital heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Journal of the American College of Cardiology. 2019 Mar 25;73(12):e81-192.
- Tobis J, Shenoda M. Percutaneous treatment of patent foramen ovale and atrial septal defects. Journal of the American College of Cardiology. 2012 Oct 30;60(18):1722-32.